Arizona Liver Health

Our Chief Medical Officer, Naim Alkhouri, MD, FAASLD, shares insights from his time in Milan, Italy, at the EASL Congress. Discover the exciting phase 2 trials and newly FDA-approved medications he highlights, which show promising results for MASH resolution and fibrosis regression. #ALH #ArizonaLiverHealth #EASL Anita Kohli Richard Manch Tessa Janovsky Ann Moore Angie Coste Yessica Sachdeva Esteban Lugo Morales Reichard R. EASL | The Home of Hepatology Jörn M. Schattenberg Mazen Noureddin, MD, MHSc Fatty Liver Alliance Madrigal Pharmaceuticals Michelle Jones Nick Engelke Kelly Black Anne Payne Desirae Trotter

We're #hiring a new Senior Clinical Research Coordinator in Tucson, Arizona. Apply today or share this post with your network.

Join us for an insightful roundtable webinar with our Chief Medical Officer, Dr. Naim Alkhouri, discussing the identification and treatment of PFIC and Wilson disease. Tune in this Thursday, July 11th, from 6-7pm ET. Register now at: www.liveralliance.org #ArizonaLiverHealth ##LiverHealth #NortheastOhioLiverAlliance Naim Alkhouri, MD, FAASLD Anita Kohli Richard Manch Ann Moore Yessica Sachdeva Angie Coste Esteban Lugo Morales Reichard R. Northeast Ohio Liver Alliance Pierre Gholam Mousab Tabbaa Mirum Pharmaceuticals, Inc. Ipsen PFIC Network Rohit Kohli, MBBS, MS Nadia Ovchinsky, MD, MBA, FAASLD Michelle Jones Nick Engelke Kelly Black Anne Payne Desirae Trotter

Celebrating an early birthday for our amazing Chief Medical Officer, Dr. Naim Alkhouri, with our wonderful Tucson team. We’re so fortunate to have you, Dr. Alkhouri. Happy Birthday! 🎉🎂 #ArizonaLiverHealth #ALH #HappyBirthday Naim Alkhouri, MD, FAASLD Anita Kohli Richard Manch Yessica Sachdeva Ann Moore Jörn M. Schattenberg Esteban Lugo Morales Reichard R. Angie Coste Mazen Noureddin, MD, MHSc Fatty Liver Alliance Rich McDonald Michelle Jones Nick Engelke Kelly Black Anne Payne Desirae Trotter

Celebrate freedom, unity, and the American spirit this 4th of July! Let’s honor the bravery of those who fought for our independence and enjoy the fireworks with loved ones. Here's to a day filled with pride, joy, and patriotism!

Iqirvo®, the latest FDA approved treatment for PBC offers new hope for patients affected by the disease. Check out what nurse practitioner and Vice President of Clinical Services, Ann Moore, had to say about the new release, "Treatment for a rare liver disease, Primary Biliary Cholangitis (PBC) continues to evolve. PBC is an autoimmune inflammatory liver disease that can progress slowly in some people, while others may develop advanced liver disease much more rapidly. The approval of PBC medications ursodiol in 1996 and obeticholic acid (Ocaliva) in 2017 changed the natural history of PBC, offering hope to many patients living with PBC. Early diagnosis is essential so that we can treat the disease to slow the rate of progression and minimize the amount of damage and scarring to the liver which in turn reduces the risk of cirrhosis and other possible complications of liver disease. Elafibranor (Iqirvo) is the latest PBC medication to receive FDA approval in June 2024 and is a first-in-class oral, once-daily peroxisome proliferator-activated receptor (PPAR) agonist. For a significant number of patients with PBC who have not fully responded to their PBC medication regimen, Iqirvo offers an additional option to optimize PBC treatment outcomes. ALH is excited to have another PBC treatment choice available in our quest to develop effective PBC treatment plans for our patients." - Ann Moore, FNP-C #iqirvo #elafibranor #primarybiliarycholangitis #pbc Ann Moore Naim Alkhouri, MD, FAASLD Anita Kohli Richard Manch Ipsen Michelle Jones Kelly Black Nick Engelke Chelsea Ann Mihaylo Hum, PMP Anne Payne Marianne Rosati Yessica Sachdeva

Advance Your Liver Disease Expertise!    Arizona Liver Health is proud to present the ALH | ACT Learning Academy’s Advanced MASLD Learning Preceptorship Program, designed for healthcare professionals seeking to enhance their understanding of MASLD/MASH. Key Components:  - Hands-on workshops: Gain practical experience with FibroScan® and Hepatoscope™, learning how to interpret results and integrate noninvasive testing into your clinical practice.  - Noninvasive test utilization: Understand the criteria for selecting patients who would benefit from pharmacologic treatment based on noninvasive test results, improving early intervention and management.  - Interactive sessions: Participate in in-depth discussions with MASLD patients and faculty, exploring real-world cases and clinical scenarios to enhance your decision-making skills. Transform your approach to liver disease treatment and care.   📅 Register now: https://lnkd.in/gBmT6-Zp   📧 Inquiries: [email protected] #MedicalEducation #LiverHealth #MASLD #HealthcareTraining Naim Alkhouri, MD, FAASLD Anita Kohli Richard Manch Ann Moore Tessa Janovsky Mazen Noureddin, MD, MHSc Meena Bansal Echosens Boehringer Ingelheim Novo Nordisk Madrigal Pharmaceuticals Nick Engelke Kelly Black Anne Payne Desirae Trotter Michelle Jones Chelsea Ann Mihaylo Hum, PMP

Today we honor Juneteenth, a day that marks the end of slavery in the United States and celebrates freedom, resilience, and the ongoing fight for justice. Let’s reflect on the struggles and triumphs of the past, and commit to building a future of equality and inclusion for all. #Juneteenth #ACT #ALH #VEN #CRIOH #FreedomDay #EqualityForAll Naim Alkhouri, MD, FAASLD Anita Kohli Richard Manch Ann Moore Yessica Sachdeva Esteban Lugo Morales Reichard R. Tessa Janovsky Fatty Liver Alliance Michelle Harris Nick Engelke Kelly Black Anne Payne Desirae Trotter

Our very own Chief Meidcal Officer, Naim Alkhouri, MD, FAASLD joined a very important podcast with Jörn M. Schattenberg and Mazen Noureddin, MD, MHSc, where they discussed the latest and most important trials from EASL/ILC. A special thank you to Roger Green for bringing the MASH community together. The future looks promising as we move from the "MASH graveyard" to the "MASH gift shop"! #LiverHealth #MASHCommunity #EASL #ILC #MedicalAdvancements Anita Kohli Richard Manch Tessa Janovsky Ann Moore Angie Coste Yessica Sachdeva Esteban Lugo Morales Reichard R. EASL | The Home of Hepatology Fatty Liver Alliance Madrigal Pharmaceuticals Michelle Jones Nick Engelke Kelly Black Anne Payne Desirae Trotter

Elevate Your Team’s Knowledge with Our MASLD Preceptorship Program!   Arizona Liver Health’s ALH | ACT Learning Academy is excited to offer a unique learning opportunity through our Advanced MASLD Learning Preceptorship Program. This non-CME training includes didactic lectures, hands-on sessions, and interactive experiences with leading specialists. Program Highlights:  Understanding MASLD spectrum: Explore the pathophysiology and clinical features of MASLD/MASH, and learn about its progression from simple steatosis to advanced fibrosis and cirrhosis.  Utilizing noninvasive tests: Master the use of tools like FibroScan® and Hepatoscope™ to identify patients at risk of advanced liver disease, enabling timely and effective intervention.  Patient interaction: Engage with MASLD patients to understand their journey, challenges, and the impact of the disease on their quality of life. Discuss current practices with providers to gain practical insights.  Empower your Team with the latest knowledge and skills. Join us to lead the fight against liver disease! 📞 For more info: 303-406-1735  📧 Contact: Michelle Jones, [email protected]   🌐 Learn more: www.azliver.com Submit Requests:  https://lnkd.in/gBmT6-Zp   #Healthcare #LiverDisease #MedicalTraining #Innovation Naim Alkhouri, MD, FAASLD Anita Kohli Richard Manch Ann Moore Tessa Janovsky Mazen Noureddin, MD, MHSc Meena Bansal Boehringer Ingelheim Novo Nordisk Madrigal Pharmaceuticals Michelle Jones Nick Engelke Kelly Black Anne Payne Desirae Trotter